Latest News about ARGX
Recent news which mentions ARGX
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
June 27, 2023
From Benzinga
From Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
From Benzinga
From Benzinga
From MarketWatch
From Benzinga
From Benzinga
From Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
From InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
April 12, 2023
From Benzinga
From Benzinga
Immunovant Could Potentially Be An M&A Target, Writes Analyst
February 15, 2023
From Benzinga
From Benzinga
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
December 22, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
From Benzinga
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
November 30, 2022
From Benzinga
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
November 22, 2022
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.